Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte: This Profitable Biotech Trades Like A Melting Iceberg
Incyte's Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 showcased 20% sales growth, 200%+ EBIT expansion, and EPS up 111%, proving operating leverage and validating management's shift of capital into higher‑return franchises. I view CALR antibody 989, povorcitinib in HS, and two de‑risking solid‑tumor agents as multiple, independent shots at post‑Jakafi multi‑billion‑dollar revenue pillars.
Incyte: Riding Jakafi, Bracing For Generic Headwinds
Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura sales, improved profitability, and disciplined R&D spending. Key risks include heavy reliance on Jakafi, with generics expected in 2028, and the pipeline's limited ability to fully offset lost revenue.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Incyte (INCY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Incyte Corporation ( INCY ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good morning.
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.
Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So welcome to this fireside chat with Incyte.
Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio
Incyte Corporation remains a Buy supported by strong Q3 2025 earnings, robust revenue growth, and raised full-year 2025 guidance. INCY advances its pipeline with promising data for povorcitinib in HS, PN, vitiligo, and asthma, with regulatory filings expected by early 2026. Oncology portfolio expansion is driven by INCA33890 for MSS colorectal cancer and INCB161734 for KRASG12D-mutated PDAC, both showing encouraging response rates.
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
